Contu A, Olmeo N A, Pani P, Deriu A, Ortu S, Paga C
Medical Oncology Dept, Civil Hospital, Sassari, Italy.
Tumori. 1991 Feb 28;77(1):52-5. doi: 10.1177/030089169107700113.
The activity of lonidamine (a derivative of indazole-carboxylic acid and a new drug with a characteristic antitumor activity) was evaluated in non-small-cell lung cancer (NSCLC). Twenty-five patients with NSCLC with or without prior treatment received lonidamine at the dose of 450 mg/daily p.o. up to progression. Objective responses obtained were: 3 (12%) partial responses and 3 (12%) minor responses with a mean duration of 13.7 weeks for partial responses. Mean duration of treatment was 20 weeks (range 4-97+). During to the drug's characteristics, bone marrow toxicity was not observed; myalgia and mild testicular pain were the most significant side effects.
对氯尼达明（吲唑羧酸衍生物，一种具有独特抗肿瘤活性的新药）在非小细胞肺癌（NSCLC）中的活性进行了评估。25例非小细胞肺癌患者，无论是否接受过先前治疗，均口服氯尼达明，剂量为450mg/日，直至病情进展。获得的客观缓解为：3例（12%）部分缓解和3例（12%）轻微缓解，部分缓解的平均持续时间为13.7周。平均治疗持续时间为20周（范围4 - 97 +）。由于该药物的特性，未观察到骨髓毒性；肌痛和轻度睾丸疼痛是最显著的副作用。
